LACTB and lymphoma: The factors associated with higher mortality or reinfection were the history of lymphoma (HR 9; 95% CI 1.004–81.2; P = 0.05) and definitive treatment with beta-lactam associated with beta-lactamase inhibitor (HR 8.4; CI 95% 1.5–46.1; P = 0.01).